What is the recommended treatment for pertussis in an adult?

Treatment for Pertussis in Adults

Treat adults with pertussis using azithromycin 500 mg on day 1, followed by 250 mg daily on days 2-5, as this is the CDC-recommended first-line regimen with superior tolerability compared to erythromycin. 1

Primary Treatment Options

First-Line: Azithromycin (Preferred)

• Dosing: 500 mg orally on day 1, then 250 mg daily on days 2-5 (total 5-day course) 1
• Advantages: Once-daily dosing, shorter treatment duration, and significantly fewer gastrointestinal side effects compared to erythromycin (RR 0.66,95% CI 0.52-0.83) 2
• Common side effects: Abdominal discomfort, diarrhea, nausea, vomiting, headache, and dizziness 1
• Precautions: Use with caution in patients with impaired hepatic function 1
• Drug interactions: Avoid concurrent use with aluminum- or magnesium-containing antacids; monitor when used with drugs metabolized by cytochrome P450 (e.g., digoxin, triazolam, ergot alkaloids) 1

Alternative: Erythromycin

• Dosing: 2 g per day in 4 divided doses (500 mg four times daily) for 14 days 1
• Rationale for 14 days: Relapses have been reported after 7-10 day courses, necessitating the longer duration 1
• Side effects: More frequent and severe gastrointestinal irritation (epigastric distress, abdominal cramps, nausea, vomiting, diarrhea) compared to azithromycin 1
• Serious contraindications: Do not use with astemizole, cisapride, pimazole, or terfenadine due to risk of QT prolongation, cardiac arrest, and torsades de pointes 1
• Drug interactions: Inhibits CYP3A enzymes, requiring careful monitoring with many medications 1

Alternative for Macrolide Intolerance: Trimethoprim-Sulfamethoxazole (TMP-SMZ)

• Dosing: Trimethoprim 320 mg/sulfamethoxazole 1,600 mg per day in 2 divided doses for 14 days 1
• Indications: Use when macrolides are contraindicated, not tolerated, or in cases of macrolide-resistant Bordetella pertussis (though resistance remains rare) 1
• Effectiveness: Clinical studies demonstrate effectiveness in eradicating B. pertussis from the nasopharynx 1
• Side effects: Gastrointestinal effects, hypersensitivity skin reactions; rarely Stevens-Johnson syndrome, toxic epidermal necrolysis, blood dyscrasias, hepatic necrosis 1
• Precautions: Use with caution in hepatic/renal impairment, folate deficiency, blood dyscrasias; maintain adequate fluid intake to prevent crystalluria 1

Clinical Context and Timing

When to Treat

• Initiate treatment within 3 weeks of cough onset to reduce communicability within 5 days, regardless of test results 3
• After 3 weeks: Antibiotics do not alter the clinical course but still prevent transmission 2, 3
• Key principle: Although antibiotics effectively eliminate B. pertussis, they do not significantly alter the subsequent clinical course of illness once the paroxysmal stage is established 2

Diagnostic Considerations

• Clinical case definition for reporting: Cough ≥2 weeks PLUS (paroxysms OR whoop OR post-tussive emesis) 3
• Testing reliability: Culture and PCR are reliable within 3 weeks of cough onset; testing is unreliable after 3 weeks 3
• Adult presentation caveat: Classic symptoms (paroxysmal cough, inspiratory whoop, post-tussive emesis) may be absent in adults, who often present with cough alone 3

Important Clinical Pitfalls

Equivalence of Short-Course Macrolides

Research demonstrates that 7 days of erythromycin is as effective as 14 days for bacteriological eradication (failure rates 2.70% vs 1.06%, not statistically different) 4. Similarly, azithromycin for 3-5 days and clarithromycin for 7 days are equally effective as erythromycin for 10-14 days in eradicating B. pertussis (RR 1.02,95% CI 0.98-1.05) 2. However, CDC guidelines still recommend the full 14-day course for erythromycin due to documented relapses with shorter courses 1.

Transmission Prevention Priority

• High contagiousness: Pertussis has 80% transmission rate 3
• Treatment reduces communicability within 5 days 3
• Critical for protecting vulnerable populations: Infants <12 months are at highest risk for severe complications and death 5, 3
• Isolation: Patients should be excluded from community settings for 5 days after starting effective antibiotic treatment 6

Medications NOT Recommended

Ampicillin, amoxicillin, tetracyclines, chloramphenicol, fluoroquinolones, and cephalosporins are not recommended despite in vitro activity, as clinical effectiveness has not been demonstrated and some have failed to clear B. pertussis from the nasopharynx 1. Note: Recent data suggest levofloxacin may be effective 7, but this is not yet incorporated into established guidelines.

Post-Exposure Prophylaxis Considerations

If the adult patient is a household contact of a pertussis case or has exposed vulnerable individuals (infants <12 months, pregnant women in third trimester), use the same antibiotic regimens as for treatment 1. Prophylaxis should be administered within 21 days of cough onset in the index patient 1.